Oncological Outcomes of Chromophobe Versus Clear Cell Renal Cell Carcinoma: Results from A Contemporary Turkish Patient Cohort
Urology Journal,
Vol. 21 No. 05 (2024),
12 October 2024
,
Page 320-324
https://doi.org/10.22037/uj.v21i.8055
Abstract
Purpose: To compare the oncological outcomes of clear cell RCC (ccRCC), which is common in renal cell carcinomas (RCC), and chromophobic RCC (chRCC), which is less common, and to define the factors affecting survival in the Turkish patient population for both RCC subclassifications.
Materials and Methods: Patients with a pathologically confirmed RCC diagnosis after radical or partial nephrectomy in the Turkish Urooncology Association (TUOA), Urological Cancers Database-Kidney (UroCaD-K), were retrospectively reviewed. Patients with ccRCC and chRCC were included in the study. Primary outcomes of this study are recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS) for each histological subtype.
Results: Data from 5300 patients in the TUOA UroCaD-K are reviewed and a total of 2560 patients (2225 in the ccRCC group and 335 in the chRCC group) are included in the final analysis. In the comparison of the groups, tumor size was greater both radiologically and pathologically in chRCC (p=0.019 vs 0.002 respectively). Recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS) rates are worse in ccRCC subgroup. In the evaluation of risk factors; pathological stage, local invasion and Fuhrmann grade were found to be significant for recurrence in ccRCC. Age, body mass index and pathological stage were the risk factors affecting overall mortality (OM). Pathological tumor size was an independent risk factor for recurrence in chRCC, while age was analyzed as the only parameter affecting OM.
Conclusion: chRCC oncological data and OS, CSS and RFS rates were found to be better than ccRCC in the Turkish patient population.
- kidney cancer
- chromophobe renal cell carcinoma (RCC)
- clear cell renal cell carcinoma(ccRCC)
- survival
- recurrence
How to Cite
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70 :7-30.
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published correction appears in CA Cancer J Clin. 2020 Jul;70(4):313]. CA Cancer J Clin. 2018;68:394-424.
Siegel, R.L., Miller, K.D., Jemal, A., 2019. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7–34.
Rini, B.I., Campbell, S.C., Escudier, B., 2009. Renal cell carcinoma. Lancet 373, 1119-32.
Davis, C. F., Ricketts, C. J., Wang, M., et al. 2014. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer cell, 26, 319–30.
Patard, J. J., Leray, E., Rioux-Leclercq, N., et al. 2005. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J. Clin. Oncol., 23, 2763–71.
Volpe, A., Novara, G., Antonelli, A., et al. Surveillance and Treatment Update on Renal Neoplasms (SATURN) Project, & Leading Urological No-Profit Foundation for Advanced Research (LUNA) Foundation 2012. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series. BJU international, 110, 76–83.
Crotty TB, Farrow GM, Lieber MM. Chromophobe cell renal carcinoma: clinicopathological features of 50 cases. J Urol. 1995;154: 964–67.
Peyromaure, M., Misrai, V., Thiounn, N., et al. 2004. Chromophobe renal cell carcinoma: analysis of 61 cases. Cancer, 100, 1406–10.
Simone G, Tuderti G, Ferriero M, et al. Papillary type 2 versus clear cell renal cell carcinoma: Survival outcomes. Eur J Surg Oncol. 2016;42:1744-50.
Cetin T, Celik S, Sozen S,et al . Oncological outcomes of papillary versus clear cell renal cell carcinoma in pT1 and pT2 stage: Results from a contemporary Turkish patient cohort. Arch Ital Urol Androl. 2023 ;95:112-18.
Gokalp F, Celik S, Sozen TS, et al. Oncological Outcomes of Patients with Non-Clear Cell Renal Cell Cancers: Subtypes of Unclassified and Translocation Renal Cell Cancers. Urol J. 2022; 20: 29-33.
Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol 1997;183:131–133.
Harris PA,Taylor R,Thielke R, et al. Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377-81.
Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208.
Seaman, E., Goluboff, E.T., Ross, S., et al. 1996. Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma. Urology 48, 692–95.
Gudbjartsson, T., Thoroddsen, A., Petursdottir, V., et al. 2005. Effect of incidental detection for survival of patients with renal cell carcinoma: results of population-based study of 701 patients. Urology 66, 1186–91.
Przybycin, C.G., Cronin, A. M., Darvishian, F., et al. 2011. Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution. Am J Surg Pathol, 35, 962–70.
Keizman, D., Sarid, D., Lee, J. L., et al. 2016. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib. The Oncologist, 21, 1212–17.
Maiti, A., Brown, R. E., Corn, P. G., et al. (2016). Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates. Clin. Genitourin. Cancer, 14, 187–93.
Rouvinov K, Osyntsov L, Shaco-Levy R, Baram N, Ariad S, Mermershtain W. Rapid Response to Nivolumab in a Patient with Sarcomatoid Transformation of Chromophobe Renal Cell Carcinoma. Clin Genitourin Cancer. 2017;15: 1127-30.
Kroeger, N., Xie, W., Lee, J. L., et al. 2013. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer, 119, 2999–3006.
Voss, M. H., Molina, A. M., Chen, Y. B., et al. 2016. Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma. J. Clin. Oncol., 34, 3846–53.
Amin, M. B., Paner, G. P., Alvarado-Cabrero, I., et al. 2008. Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol, 32, 1822–34.
Sharma R, Kaushal V. Sarcomatoid chromophobe renal cell carcinoma: A rare entity with prognostic significance. J Cancer Res Ther. 2015;11:1030.
Lauer SR, Zhou M, Master VA, et al. Chromophobe renal cell carcinoma with sarcomatoid differentiation: a clinicopathologic study of 14 cases. Anal Quant Cytopathol Histpathol. 2013;35:77–84.
Ged, Y., Chen, Y. B., Knezevic, A., et al. 2019. Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. Clin. Genitourin. Cancer, 17, 678–88.
Frees, S., Kamal, M. M., Knoechlein, L., et al. 2016. Differences in Overall and Cancer-specific Survival of Patients Presenting With Chromophobe Versus Clear Cell Renal Cell Carcinoma: A Propensity Score Matched Analysis. Urology, 98, 81–87.
Daugherty, M., Blakely, S., Shapiro, O., et al. 2016. Chromophobe Renal Cell Carcinoma is the Most Common Nonclear Renal Cell Carcinoma in Young Women: Results from the SEER Database. J Urol, 195, 847–51.
Patard, J. J., Leray, E., Rioux-Leclercq, N., et al. 2005. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J. Clin. Oncol. 23, 2763–71.
Casuscelli, J., Becerra, M. F., Seier, K., et al. 2019. Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series. Clinical genitourinary cancer, 17, 373–79.
- Abstract Viewed: 561 times
- 8055/pdf Downloaded: 298 times